Lupin launches Bupropion Hydrochloride Extended Release Tablets

In United States

Lupin announced the launch of its Bupropion Hydrochloride Extended Release Tablets USP, 150 mg and 300 mg having received an approval from the USFDA earlier. It is the AB rated generic equivalent of Valent Pharmaceuticals North America, LLC's Wellbutrin XL tablets, 150 mg and 300 mg, which is indicated for the treatment of major depressive disorders and prevention of seasonal affective disorders in adults.

Powered by Capital Market - Live News